SAGE Therapeutics (SAGE) said Thursday it is cutting its workforce by 165 employees as part of a business reorganization, which it said it expects to be completed by the end of the year.
The biopharmaceutical company said the cuts equate to approximately 33% of its total workforce and approximately 55% of its research and design team.
SAGE also said it expects a non-recurring charge of approximately $26 million to $28 million related to the reorganization, most of which it said it will incur in Q4.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。